Positive real-world results for Takeda UC therapy

3 June 2018

Japanese drugamker Takeda (TYO: 4502) has revealed new real-world data that paints a favorable picture of its Crohn's disease and ulcerative colitis therapy Entyvio (vedolizumab).

The drug, a gut-selective immunosuppressive monoclonal antibody, first hit the market in the USA and Europe 2014. The VICTORY Consortium was launched in the same year, and currently keeps track of around 1,700 Entyvio patients to monitor their symptoms and side effects.

Patients taking Entyvio showed reduced rates of serious infections (4.1% versus 10.1% on tumor necrosis factor-alpha (TNFa) therapies) and significantly reduced rates of significant adverse reactions (4.7% versus 14.5% on TNFa).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK